MagnesiumMagnesium: According to human and animal studies, electrolyte disturbances, including low magnesium levels, may develop in a large proportion of patients receiving amphotericin B (12134234, 9177994, 2182052). According to human and animal studies, lipid-based formulations such as Abelcet® and Anphotec® may have a lesser effect than conventional formulations (2182052). This disturbance has been associated with nephrotoxicity and may necessitate discontinuing the drug and administering intravenous electrolyte replacement.
PotassiumPotassium: According to animal study, amphotericin B (AMP-B) may induce potassium excretion defects (7948785). Hypokalaemia may be associated with acute myeloid leukemia after fluconazole treatment in humans (2565490).
The information in this monograph is intended for informational purposes only, and is meant to help users better understand health concerns. Information is based on review of scientific research data, historical practice patterns, and clinical experience. This information should not be interpreted as specific medical advice. Users should consult with a qualified healthcare provider for specific questions regarding therapies, diagnosis and/or health conditions, prior to making therapeutic decisions.